12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Deals

Stallergenes, Shionogi deal

Stallergenes granted Shionogi exclusive rights to develop and commercialize allergy candidate Actair in Japan and Taiwan. The sublingual desensitization tablet to treat house dust mites...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >